• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[肿瘤坏死因子-α基因多态性对沙利度胺方案治疗多发性骨髓瘤疗效的影响]

[Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma].

作者信息

DU Juan, Yuan Zhen-Gang, Zhang Chun-Yang, Fu Wei-Jun, Jiang Hua, Chen Bao-An, Hou Jian

机构信息

Southeast University Medical School, Nanjing 210009, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2009 Oct;30(10):649-53.

PMID:19954656
Abstract

OBJECTIVE

To evaluate the effect of polymorphism at the -238 and -308 position of the TNF-alpha promotor region on the clinical outcome of thalidomide (Thal)-based regimens for the treatment of multiple myeloma (MM).

METHODS

The polymorphism at the -238 and -308 position of the TNF-alpha promotor region of 168 MM patients treated with Thal-based regimens were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genotypes were tested for association with overall response by logistic regression, and survival was evaluated by univariate and multivariate analysis.

RESULTS

In TNF-alpha -238 position, 11 (6.5%) patients had GA genotype and 1 (0.6%) AA genotype. In TNF-alpha -308 position, 19 (11.3%) had GA genotype and 1 (0.6%) AA genotype. In univariate analysis, the TNF-alpha -238 GA + AA genotypes were associated with a significantly prolonged progression free survival (PFS) (P = 0.017), and a better overall survival (OS) (P = 0.150). Multivariate COX regression analysis showed that TNF-alpha -238 polymorphic status was an independent prognostic factor for prolonged PFS (P = 0.049).

CONCLUSION

The TNF-alpha -238 polymorphic status is associated with a favorable clinical outcome in MM patients treated with thalidomide-based regimen. The polymorphism status of TNF-alpha gene might be of promise for developing a more informative stratification system for MM.

摘要

目的

评估肿瘤坏死因子-α(TNF-α)启动子区域-238和-308位点的多态性对沙利度胺(Thal)方案治疗多发性骨髓瘤(MM)临床疗效的影响。

方法

采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法,对168例接受Thal方案治疗的MM患者TNF-α启动子区域-238和-308位点的多态性进行检测。通过逻辑回归分析基因型与总缓解率的相关性,并采用单因素和多因素分析评估生存率。

结果

在TNF-α -238位点,11例(6.5%)患者为GA基因型,1例(0.6%)为AA基因型。在TNF-α -308位点,19例(11.3%)为GA基因型,1例(0.6%)为AA基因型。单因素分析显示,TNF-α -238 GA + AA基因型与无进展生存期(PFS)显著延长相关(P = 0.017),总生存期(OS)较好(P = 0.150)。多因素COX回归分析表明,TNF-α -238多态性状态是PFS延长的独立预后因素(P = 0.049)。

结论

TNF-α -238多态性状态与接受Thal方案治疗的MM患者良好的临床疗效相关。TNF-α基因的多态性状态可能有助于为MM建立更具信息性的分层系统。

相似文献

1
[Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma].[肿瘤坏死因子-α基因多态性对沙利度胺方案治疗多发性骨髓瘤疗效的影响]
Zhonghua Xue Ye Xue Za Zhi. 2009 Oct;30(10):649-53.
2
Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.TNF-α 启动子多态性在沙利度胺联合地塞米松治疗多发性骨髓瘤中的作用及其对临床结局的影响。
Leuk Res. 2010 Nov;34(11):1453-8. doi: 10.1016/j.leukres.2010.01.011. Epub 2010 Jan 31.
3
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.白细胞介素 1B 基因启动子区域的单核苷酸多态性影响接受高剂量化疗的多发性骨髓瘤患者的预后,而与沙利度胺和硼替佐米的缓解治疗无关。
Ann Hematol. 2011 Oct;90(10):1173-81. doi: 10.1007/s00277-011-1194-3. Epub 2011 Feb 24.
4
[Molecular genetic analysis of the interleukin 6 and tumor necrosis factor alpha gene polymorphisms in multiple myeloma].多发性骨髓瘤中白细胞介素6和肿瘤坏死因子α基因多态性的分子遗传学分析
Mol Biol (Mosk). 2003 May-Jun;37(3):420-4.
5
A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
Haematologica. 2004 May;89(5):552-6.
6
Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.
Blood. 2002 Sep 15;100(6):2263-5.
7
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.沙利度胺对复发多发性骨髓瘤总生存期的剂量依赖性效应。
Clin Cancer Res. 2002 Nov;8(11):3377-82.
8
[The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients].沙利度胺治疗多发性骨髓瘤的疗效:102例中国患者的临床分析
Zhonghua Xue Ye Xue Za Zhi. 2008 Apr;29(4):226-9.
9
Lack of association between TNF-α promoter polymorphisms and multiple myeloma: a meta-analysis.TNF-α 启动子多态性与多发性骨髓瘤无关:一项荟萃分析。
Leuk Res. 2013 Jan;37(1):50-7. doi: 10.1016/j.leukres.2012.08.027. Epub 2012 Sep 20.
10
Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma.多发性骨髓瘤中肿瘤坏死因子-α和淋巴毒素-α基因的多态性
Leuk Res. 2008 Oct;32(10):1499-504. doi: 10.1016/j.leukres.2008.03.001. Epub 2008 Apr 10.

引用本文的文献

1
Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.炎症与抗炎平衡、增殖与抗增殖平衡:细胞因子在多发性骨髓瘤中的作用。
Mediators Inflamm. 2017;2017:1852517. doi: 10.1155/2017/1852517. Epub 2017 Sep 26.